Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year
27 October 2023 - 5:00AM
Business Wire
– Annual Survey has Ranked Alnylam within the
Top Three on the Best Employers List Since 2019 –
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced its third place ranking in Science
magazine’s Top Employer Survey for 2023. This marks the fifth year
that Alnylam was featured as one of the top three companies in the
annual survey of more than 6,800 professionals across
biotechnology, biopharmaceuticals, and related industries.
“As a science-based organization, it’s critically important to
us that Alnylam be regarded as a great place to work for people
looking for a challenging and rewarding career at a company that is
at the forefront of scientific discovery,” said Kevin Fitzgerald,
Ph.D., Chief Scientific Officer. “It is equally important to us to
be known for a workplace culture that makes it possible for all of
our people to thrive and grow while supporting our mission to
deliver transformative RNAi therapies for patients. That’s why
ongoing recognition from Science magazine as a top place to work is
so gratifying.”
Respondents to the web-based survey were asked to rate companies
based on 24 characteristics, including innovative leadership,
respect for employees, and social responsibility. Survey
respondents came from all over the world with 59% from North
America, 18% from Europe, and 16% from the Asia/Pacific Rim.
Alnylam’s top attributes included, “Treats employees with
respect”; “Is socially responsible”; and “Has work culture values
that are aligned with employee’ personal values”.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation
of RNA interference (RNAi) into a whole new class of innovative
medicines with the potential to transform the lives of people
afflicted with rare and prevalent diseases with unmet need. Based
on Nobel Prize-winning science, RNAi therapeutics represent a
powerful, clinically validated approach yielding transformative
medicines. Since its founding in 2002, Alnylam has led the RNAi
Revolution and continues to deliver on a bold vision to turn
scientific possibility into reality. Alnylam’s commercial RNAi
therapeutic products are ONPATTRO® (patisiran), AMVUTTRA®
(vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and
Leqvio® (inclisiran), which is being developed and commercialized
by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of
investigational medicines, including multiple product candidates
that are in late-stage development. Alnylam is executing on its
“Alnylam P5x25” strategy to deliver transformative medicines in
both rare and common diseases benefiting patients around the world
through sustainable innovation and exceptional financial
performance, resulting in a leading biotech profile. Alnylam is
headquartered in Cambridge, MA. For more information about our
people, science and pipeline, please visit www.alnylam.com and
engage with us on X (formerly Twitter) at @Alnylam, on LinkedIn, or
on Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231026365139/en/
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom
(Investors and Media) +1-617-682-4340 Josh Brodsky (Investors)
+1-617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2024 to May 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From May 2023 to May 2024